You are here

FDA Accepts Application for Promethazine/ Hydrocodone/ Acetaminophen Painkiller

Approval decision scheduled for January 2017

The FDA has accepted for review a new drug application for CL-108 (Charleston Laboratories/Daiichi Sankyo) for the relief of moderate-to-severe pain while preventing or reducing the associated opioid-induced nausea and vomiting. CL-108 is a fixed-dose, immediate-release, bilayered tablet with a rapid-release layer containing 12.5 mg of promethazine and a second layer containing 7.5 mg of hydrocodone and 325 mg of acetaminophen.

The FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of January 31, 2017.

The new drug application for CL-108 was supported by two pivotal randomized, double-blind, placebo- and active-controlled phase 3 clinical studies, one after oral surgery (molar removal) and the other after bunionectomy surgery, as well as by an additional phase 3 open-label, actual-use safety study in patients with moderate-to-severe acute pain or “flares” associated with osteoarthritis of the knee or hip. More than 1,000 patients have been enrolled in the CL-108 phase 3 clinical trial program. A human abuse-liability study has also been conducted.

Source: Charleston Laboratories; June 14, 2016.

Recent Headlines

Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status
Kadcyla Cut Risk of Recurring Disease by Half Compared to Herceptin
May Lead to Personalized Treatment for Schizophrenia, Other Illnesses
First Medicines for Adults With Wild-type or Hereditary ATTR-CM